Literature DB >> 1320540

Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.

C C Lang1, J G Motwani, W J Coutie, A D Struthers.   

Abstract

1. Brain natriuretic peptide is a new natriuretic hormone with striking similarity to atrial natriuretic peptide, but there are no previous data concerning its clearance in man. Two pathways of clearance for atrial natriuretic peptide are recognized: degradation by neutral endopeptidase and binding to atrial natriuretic peptide clearance receptors. We have examined the effect of candoxatril, an inhibitor of neutral endopeptidase (dose range 10-200 mg), and the effect of an infusion of a pharmacological dose [45 micrograms (90 micrograms in two patients)] of synthetic human atrial natriuretic peptide on plasma human brain natriuretic peptide-like immunoreactivity levels in seven patients with mild to moderate chronic heart failure. 2. Plasma human brain natriuretic peptide-like immunoreactivity levels were elevated in all patients (mean +/- SEM 22.0 +/- 6.2 pmol/l) compared with healthy control subjects (1.3 +/- 0.2 pmol/l, n = 11). 3. In all patients, candoxatril increased both plasma atrial natriuretic peptide (P less than 0.05) and plasma human brain natriuretic peptide-like immunoreactivity (P less than 0.05) levels. 4. By contrast, an exogenous infusion of atrial natriuretic peptide had no effect on plasma human brain natriuretic peptide-like immunoreactivity levels despite increasing the plasma atrial natriuretic peptide concentration to 424 +/- 74 pmol/l, which is a level of atrial natriuretic peptide which would have 'swamped' all atrial natriuretic peptide clearance receptors. 5. We have therefore shown that plasma human brain natriuretic peptide-like immunoreactivity levels in chronic heart failure are increased by a neutral endopeptidase inhibitor, but are unchanged by an exogenous infusion of atrial natriuretic peptide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320540     DOI: 10.1042/cs0820619

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

2.  Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations?

Authors:  A D Struthers
Journal:  Br Heart J       Date:  1993-11

3.  Effect of endopeptidase-24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat.

Authors:  J E Kirk; M R Wilkins
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 4.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

5.  Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats.

Authors:  K S Park; Y Li; Y Zhang; A L Gerbes; H Liu; M G Swain; S S Lee
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats.

Authors:  Y Hashimoto; S Mori; N Hama; K Nakao; H Imura; M Yamaguchi; M Yasuhara; R Hori
Journal:  J Pharmacokinet Biopharm       Date:  1993-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.